Russian Heart Failure Journal 2008year Beta-blockers in chronic heart failure with unchanged ejection fraction

To access this material please log in or register

Register Authorize

Beta-blockers in chronic heart failure with unchanged ejection fraction

Kastanayan A. A., Nelasov N. Yu., Kaplina E. V., Gusseynova E. Sh., Nedoruba E. A.



Scarcity of clinical studies on efficacy of medicines including β-adrenoblockers in diastolic HF (DHF) is due to insufficient perception of this problem, difficulty of matching homogenous cohorts and the absence until recently of a universal definition and diagnostic criteria for DHF. However a tremendous demonstrative database is available, which supports the use of β-adrenoblockers in patients with different stages of CHF including, undoubtedly, patients with LV diastolic dysfunction (DD). Considering positive results of those studies along with well studied pharmacological properties of β-adrenoblockers they may be used for the treatment of both HF with reduced EF (HFREF) and HF with normal EF (HFNEF). Furthermore, as long as other data are not available yet, the β-adrenoblockers that have proved efficient in the treatment of systolic HF (SHF) should be probably used for the treatment of DHF.
    1.    Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355 (3):251–259.
    2.    Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics of left ventricular diastolic dysfunction in the  community: an echocardio-graphic survey. Heart. 2006;92 (9):1259–1264.
    3.    Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442–463.
    4.    Bhatia RS, Tu JV, Lee DS et al. Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study. N Engl J Med. 2006;355 (3):260–269.
    5.    Paulus WJ, Tschöpe C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28 (20):2539–2550.
    6.    Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27 (19):2338–2345.
    7.    Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105 (12):1503–1508.
    8.    Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26 (11):1115–1140.
    9.    Heart Failure Society Of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12 (1):10–38.
    10.    Mulieri LA, Hasenfuss G, Leavitt B et al. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85 (5):1743–1750.
    11.    Chen HH, Lainchbury JB, Senni M, Redfield MM. Factors influencing survival in patients with diastolic heart failure in Olmsted County, MN, in 1996–97 (abstr). Circulation 2000;102: II412.
    12.    Varadarajan P, Sharma S, Gandhi S et al. «Beneficial Effect of Beta Blockers on Survival in Congestive Heart Failure with Normal Ejection Fraction,» American College of Cardiology 54th Scientific Session, Orlando, Fla. Heart Failure: Therapy, poster session, March 7, 3:30 p. m. – 4:30 p. m., abstract No. 318452.
    13.    Ghio S, Magrini G, Serio A et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J. 2006; 27 (5):562–568.
    14.    Fonarow GC, Abraham WT, Albert NM et al. Influence of a Performance-Improvement Initiative on Quality of Care for Patients Hospitalized With Heart Failure: Results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167 (14):1493–1502.
    15.    Ahmed A, Rich MW, Fleg JL et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114 (5):397–403.
    16.    Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5 (5):621–627.
    17.    Thomas JD, Weyman AE. Echocardiographic Doppler evaluation of left ventricular diastolic function: Physics and physiology. Circulation. 1991;84 (3):977–990.
    18.    Appleton CP, Hatle LK. The natural history of left ventricular filling abnormalities: assessment by two dimensional and Doppler echocardiography. Echocardiography. 1992;9:437–445.
    19.    Giannuzzi P, Imparato A. Temporelli PL et al. Doppler-derived mitral deceleration time of early filling as strong predictor of pulmonary capillary wedge pressure in postinfarction patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 1994;23 (7):1630–1637.
    20.    Xie GY, Berk MR, Smith MD et al: Prognostic value of transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol. 1994;24 (1):132–139.
    21.    Bergström A, Andersson B, Edner M et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Am Heart J. 2000;139 (4):596–608.
    22.    Capomolla S, Febo O, Gnemmi M et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J. 2000;139 (4):584–586.
    23.    Palazzuoli A, Quatrini I, Vecchiato L et al. Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure. Minerva Cardioangiol. 2005;53 (4):321–328.
    24.    Wiklund I, Waagstein F, Swedberg K, Hjalmarsson A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Cardiovasc Drugs Ther. 1996;10 (3):361–368.
    25.    Andersson B, Caidahl K, di Lenarda A et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation. 1996;94 (4):673–682.
    26.    Andersson B, Strömblad SO, Lomsky M, Waagstein F. Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol. Eur Heart J. 1999;20 (8):575–583.
    27.    Glass MG, Reiss I, Cory R et al. Reversal of the negative treppe with ß-blockers: role of sarcoplasmic reticulum function and myocardial energetics. Circulation. 1993;88: I-526.
    28.    Hole T, Frøland G, Gullestad L et al. Metoprolol CR / XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. Echocardiography. 2004;21 (3):215–223.
    29.    MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
    30.    Eichhorn EJ, Heesch CM, Risser RC et al. Pedictors of systolic diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol. 1995;25 (1):154–162.

To access this material please log in or register

Register Authorize
Ru En